Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study

Guicciardi, Federica; Atzori, Laura; Marzano, Angelo Valerio; Tavecchio, Simona; Girolomoni, Giampiero; Colato, Chiara; Villani, Axel-Patrice; Kanitakis, Jean; Mitteldorf, Christina; Satta, Rosanna; Cribier, B.; Gusdorf, L.; Calzavara‐Pinton, Piergiacomo; Bielsa, Isabel; Fernández‐Figueras, María Teresa; Kempf, Werner; Filosa, Giorgio; Pilloni, Luca; Rongioletti, Franco

doi:10.1016/j.jaad.2019.02.009

Cited by 33 publications

(48 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fewer patients have positive La/SSB, while anti-histone and anti-ds-DNA antibody are often negative. 3–5 Ro/SS-A autoantibody rates were not significantly different between DI-SCLE and idiopathic SCLE. 5 , 6 Within most cases, Ro/SSA or La/SSB will remain positive after DI-SCLE resolution.…”

mentioning

confidence: 69%

See 1 more Smart Citation

A case of recombinant human follitropin alfa-induced subacute cutaneous lupus erythematosus presenting with erythema multiforme-like lesion

Wang

Chen

Qiang

2020

Lupus

View full text Add to dashboard Cite

mentioning

confidence: 69%

“…Among them, EM-like and bullous are mostly described. 3–5 DI-SCLE is strongly associated with Ro/SSA autoantibody and ANA with a speckled pattern. Fewer patients have positive La/SSB, while anti-histone and anti-ds-DNA antibody are often negative.…”

mentioning

confidence: 99%

A case of recombinant human follitropin alfa-induced subacute cutaneous lupus erythematosus presenting with erythema multiforme-like lesion

Wang

Chen

Qiang

2020

Lupus

View full text Add to dashboard Cite

“…Subacute DILE more frequently exhibited widespread cutaneous involvement with malar rash and was more frequently bullous or erythema multiforme-like as compared with idiopathic SCLE [45]. However, in a recent multicentric study of 232 patients, including 67 (29%) with subacute DILE, the presentation pattern or serology did not differ, except that people with subacute DILE were older than those with idiopathic SCLE [46]. A case-control study of 234 SCLE patients found subacute DILE frequently associated with use of the drugs terbinafine (OR 52.9, 95% CI 6.6-∞), TNFα inhibitors (OR 8.0, 95% CI 1.6-37.2), antiepileptics (OR 3.4, 95% CI 1.9-5.8) and proton pump inhibitors (OR 2.9, 95% CI 2.0-4.0) [47].…”

Section: Drug-induced Cutaneous Lupus and Drug Withdrawalmentioning

confidence: 93%

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review

Chasset

Françès

2019

Drugs

View full text Add to dashboard Cite

Standard treatment of cutaneous lupus erythematosus (CLE) includes preventive measures such as smoking cessation and photoprotection associated with topical therapies and antimalarial agents, which are recommended as first-line systemic treatment. In more severe disease, alternative therapeutic options include immunosuppressive and immunomodulatory drugs. Recently, the development of specific tools to assess CLE activity and the publication of European CLE guidelines have improved the management of CLE. Moreover, several biologic agents are currently studied specifically in CLE or in systemic lupus erythematosus with assessment of skin involvement and may be promising therapies. However, improvement of the management of CLE remains a major unmet need. In this review, we summarize current concepts in the management of CLE as well as future approaches for more targeted treatments. Key points:  Some targeted agents that have shown some promise in skin manifestations with systemic lupus erythematosus.  Future studies are needed specifically for cutaneous lupus erythematosus (CLE), with responses for each of the CLE subtypes reported separately.

show abstract

“…In a recent study, present ratio of DI-CLE in 232 patients is 29%. 101 A retrospective chart review reveals that 88 cases developed to DI-SCLE in Denmark, and in this review, proton-pump inhibitors, antihypertensives and antifungals are suggested to be the most common drugs; therefore, it might be important for dermatologist to recognize and use these drugs which are associated with 'lupus-precipitating'. 102…”

Section: Preventionmentioning

confidence: 97%

The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions

Zhou

Yan

et al. 2020

Scand J Immunol

View full text Add to dashboard Cite

Lupus erythematosus (LE) is an autoimmune disease with diverse and complicated aetiology, including systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). CLE is a common manifestation of SLE, resulting in disfiguring scars, permanent hair loss and significant loss of quality of life for patients. 1 According to Gilliam and Sontheimer, CLE can be subdivided into three categories: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). 2 ACLE is often associated with systemic symptoms. 3 Half of SCLE patients meet criteria for SLE, though both of ACLE and SCLE often have mild SLE symptoms. 2 CCLE includes five different forms: discoid LE (DLE), verrucous/hypertrophic LE, LE profundus/panniculitis (LEP), LE tumidus (LET) and chilblain LE (CHLE). 3 DLE is the most

show abstract

Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study

Cited by 33 publications

References 42 publications

A case of recombinant human follitropin alfa-induced subacute cutaneous lupus erythematosus presenting with erythema multiforme-like lesion

A case of recombinant human follitropin alfa-induced subacute cutaneous lupus erythematosus presenting with erythema multiforme-like lesion

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review

The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions

Contact Info

Product

Resources

About